Methotrexate (MTX) is widely utilized for the treatment of patients with rheumatoid arthritis (RA); however, recent observation of the MTX-resistant patients proposed some difficulty in MTX-dependent therapeutic approach for RA. To access cellular events related to MTX resistance in RA in respect to inflammatory bone destruction, we investigated on an involvement of the potent inflammatory mediator adenosine in the regulation of osteoclastogenesis and inflammatory bone destruction. In rats with adjuvant-induced arthritis (AA rats), MTX efficiently suppressed bone destruction when it was administrated within 3 days after adjuvant injection, while it could not suppress inflammatory bone destruction if MTX was injected at the time of onset of inflammation (at day 10 after adjuvant injection). Time-course change in the level of plasma adenosine of AA rats was estimated by use of high-performance liquid chromatography and elucidated that adenosine level was markedly elevated till 10 days after adjuvant injection. In vitro bone marrow culture system for evaluating osteoclastogenesis, MTX markedly suppressed osteoclastogenesis in a stromal cell-dependent manner. This MTX-induced suppression of osteoclastogenesis was abrogated by the addition of adenosine. MTX suppressed the expression of mRNA for the receptor activator NF-kB ligand (RANKL), but it did not suppress the expression of osteoprotegerin (OPG). The addition of MTX and adenosine together markedly suppressed the level of OPG expression. Abolishment of MTX action by adenosine was significantly blocked by MRS1754, a highly selective antagonist for the A 2b adenosine receptor (A 2b AR), but not by caffeine, an antagonist for A 1 , A 2a , A 3 AR (A 1 AR, A 2a AR, and A 3 AR), which suggests that adenosine acts through A 2b AR. Immunohistochemical studies showed abundant expression of A 2b AR in cells localized in the bone-bone marrow boundary of the distal tibia in AA rats but not in control rats. When adenosine was injected in the ankle joints of MTX-treated AA rats, the suppressive effects of MTX on bone destruction was abolished. The current data therefore suggest that upregulation of adenosine production abolished the suppressive effect of MTX on osteoclastic bone destruction. Involvement of the adenosine-A 2b AR system may explain MTX resistance in RA.
KEYWORDS: adenosine; adenosine receptor A2b; adjuvant arthritis; bone destruction; HPLC; methotrexate; osteoclast; osteoprotegerin Rheumatoid arthritis (RA) is a chronic inflammatory disease characterized by the destruction of articular cartilage and bone. Bone destruction is mediated by the multinucleated giant cells, osteoclasts. [1] [2] [3] Abundant expression of inflammatory cytokines upregulates osteoclastogenesis within the inflamed regions. Methotrexate (MTX), a monomethylated aminopterin, is widely used and is one of the most effective therapeutics for the treatment of RA. MTX and aminopterin are folic acid antagonists that act as competitive inhibitors of dihydrofolate reductase, a key enzyme of 'de novo' nucleic acid synthesis. These agents were originally developed for use in chemotherapeutic treatment of infant leukemia to inhibit proliferation of tumor cells. [4] [5] [6] MTX continues to be widely used for chemotherapy of cancer. Low-dose therapy with MTX has been shown to be effective for the treatment of RA, [7] [8] [9] and has become the gold standard for RA. However, some lines of evidence have demonstrated that MTX fails to suppress bone destruction in some RA patients. 9 , 10 The presence of MTX resistance reduces the efficacy of MTXdependent therapy. However, the molecular and cellular mechanism of MTX resistance in inflammatory bone destruction remains ambiguous. 11 Receptor activator NF-kB ligand (RANKL) is the major cytokine for osteoclastogenesis. RANKL binds to its specific receptor RANK expressed on osteoclast precursors and induces differentiation into multinucleated osteoclasts. 12 RANKL-induced osteoclastogenesis is blocked by a decoy receptor of RANKL, osteoprotegerin (OPG). [13] [14] [15] Therefore, the local RANKL/OPG ratio determines the potency of osteoclastogenesis in bone tissues.
Adenosine is a key endogenous molecule, which regulates tissue function by activating G-protein-coupled adenosine receptors (ARs). 16 So far, four types of ARs, A 1 AR, A 2a AR, A 2b AR, and A 3 AR have been identified. A 1 AR, A 2a AR, and A 3 AR are high-affinity receptors, which can be activated by physiological concentrations of extracellular adenosine of o1 mM. However, in contrast, A 2b AR is a low-affinity receptor, which requires adenosine levels that exceed 10 mM for activation. In inflammatory disease, it is known that the local adenosine level may rise to pathophysiological concentrations, enabling activation of the low-affinity receptor, A 2b AR.
Aminopterin, an unmethylated form of MTX, is routinely used for selection of B-cell hybridomas in the production of monoclonal antibodies. During the course of our trial to develop novel antibodies affecting osteoclastogenesis, we have accidentally noticed that osteoclastogenesis is markedly inhibited by aminopterin and its monomethylated derivative, MTX (unpublished observations). This paper focuses on investigating the basic cellular events underlying MTX resistance in osteoclastic bone destruction. In vitro experiments demonstrated that suppression of osteoclastogenesis by MTX was abolished by treatment with adenosine, possibly in an A 2b AR-dependent manner, through suppressing OPG expression. In vivo studies using AA rats also suggested a role of adenosine as an important modulator of bone destruction.
MATERIALS AND METHODS Materials
Heat-killed Mycobacterium butyricum and mineral oil were obtained from Difco Laboratories (Detroit, MI, USA). RANKL was purchased from Peprotech EC (London, UK). 1a,25-Dihydroxy vitamin D 3 (1a,25(OH) 2 D 3 ) was from Biomol Research Laboratories (Plymouth Meeting, UK). MTX, adenosine, cytidine, guanosine, uridine, deoxyadenosine, deoxycytidine, deoxyguanosine, thymidine, caffeine, MRS1754, and Leukocyte acid phosphatase kits were obtained from Sigma (St Louis, MO, USA). a-Minimum essential medium (aMEM; cat#12000-022) and aMEM containing nucleosides (aMEM þ Nuc; cat#11900-024) and penicillin-streptomycin were purchased from Invitrogen (Grand Island, NY, USA).
Animals and Animal Experiments and Ethics Committee Approval
Sprague Dawley (SD) rats, Lewis rats were obtained from Kyudo (Tosu, Japan). All animal experiments were performed according to the guidelines for 'Care and Use of Animals of Kyushu University'.
Measurement of Plasma Adenosine Concentration by HPLC Peripheral blood was obtained from aorta of AA rats and immediately centrifuged 800 r.p.m. at 4 1C for 5 min. Supernatants (plasma sample) were immediately frozen and kept in liquid nitrogen and maintained in it till HPLC analysis. After thawing the frozen sample, 90 ml samples were mixed with 10 ml of 60% perchloric acid followed by being mixed immediately by vortex. After centrifuge (15 000 r.p.m., 5 min, 4 1C), 50 ml supernatant was subjected to HPLC (Mighty sil RP-18GP column 4.6 mm ID Â 250 mm) (Kantoh Chemical, Tokyo, Japan). Elution was performed by 10 mM potassium phosphate (pH 2.9) and 1-8% of acetonitrile at the flowrate of 1.0 ml per second. Elution pattern was monitored by detecting UV absorbance at 260 nm. Various quantities of standard adenosine were also injected to HPLC to make a standard curve for the quantification of the sample.
Bone Marrow Culture System
Formation of osteoclast-like multinucleated cells (MNCs) from rat bone marrow cells was performed as described previously. 17, 18 Briefly, bone marrow cells were obtained from the tibia and femur of 4-6-week-old male SD rats. Cells were seeded into 24-well culture plates (10 6 cells/well) and cultured for 4 or 5 days in aMEM without or with nucleosides (aMEM þ Nuc) containing 15% FBS in the presence of 10 À8 M 1a,25(OH) 2 D 3 , 10% (v/v) heat-treated ROS17/2.8 cell-conditioned medium (ht-ROS CM) and various concentrations of MTX. Cells were fixed with acetone-citrateformaldehyde, and stained for TRAP using a leukocyte acid phosphatase kit. TRAP-positive cells containing more than three nuclei were counted as osteoclast-like MNCs. For stromal cell-free cultures, bone marrow stromal cells were depleted by Sephadex TM G-10 (GE Healthcare, Uppsala, Sweden) column as described previously. 18 The non-adherent bone marrow cells were cultured in the presence of 10 À8 M 1a,25(OH) 2 D 3 , 20 ng/ml sRANKL and 10% (v/v) htROSCM. Cells were cultured in 96-well culture plates (4 Â 10 5 cells/ well) in the presence of various concentrations of MTX. After 4 days of culture, the cells were fixed and stained with TRAP.
Preparation of Rat Primary Osteoblasts
Rat primary osteoblasts were prepared by sequential digestion of calvarias of 2-day-old SD rats with collagenase and dispase, according to the method of Takahashi et al 19 and Kukita et al.
18
Semiquantitative RT-PCR Total cellular RNA was extracted from cultured cells using TRIzol Reagent (Invitrogen, Carlsbad, CA, USA) and subjected to semiquantitative RT-PCR using RT-PCR kit (Takara, Kyoto, Japan) according to the manufacturer's protocol. The primers used for PCR were as follows: rat RANKL forward, CGT TTG CTC ACC TCA CAA TC; rat RANKL reverse, ACG CTA ATT TCC TCA CCA GC; rat OPG forward, ATT GGC TGA GTG TTC TGG TG; rat OPG reverse, GCC CAG TGA CCA TTC CTA AC; rat cathepsin K forward, TCT CTC GGC GTT TAA TTT GG; rat cathepsin K reverse, CAC ATA TGG GAA AGC ATC TTC A; rat A 1 AR forward, CAT TGG GCC ACA GAC CTA CT; rat A 1 AR reverse, CAA GGG AGA GAA TCC AGC AG; rat A 2a AR forward, CTT CGC TAT CAC CAT CAG CA; rat A 2a AR reverse, AAA TTG CAA TGA TGC CCT TC; rat A 2b AR forward, CTT TCA CAG CTG CCT CTT CC; rat A 2b AR reverse, AGT CAG TCC AAT GCC AAA GG; rat actin forward, GGG TGT GAT GGT GGG AAT G; rat actin reverse, GCT CGA AGT CTA GAG CAA CAT AGC; rat GAPDH forward, GGT GAT GCT GGT GCT GAG TA; rat GAPDH reverse, ACT GTG GTC ATG AGC CCT TC. The PCR products were subjected to electrophoresis on 1.5% agarose gels and visualized by ethidium bromide staining with UV light illumination.
Induction of Adjuvant Arthritis in Lewis Rats and X-Ray Imaging Adjuvant arthritis was induced as described previously. 20, 21 Briefly, 5-week-old female Lewis rats were intradermally injected at the base of the tail with complete adjuvant consisting of 25 mg/kg heat-killed M. butyricum (Difco Laboratories) suspended in mineral oil. In control experiments, rats were injected with mineral oil alone. All animals were anesthetized with diethyl ether prior to adjuvant injections. MTX (1 mg/kg/week) or vehicle (phosphatebuffered saline (PBS)) was injected intraperitoneally. These injections were performed once a week beginning 3 days after the adjuvant injection. Adenosine or vehicle (PBS) was injected into the ankle-joint cavities of adjuvant-injected rats. Thirty-gauge needles were used to inject 80 mg adenosine in 150 ml PBS into the left ankle joints. As an internal control, 150 ml PBS was injected into the right ankle joint. Injections were performed every 3 days beginning on the same day as MTX injections (3 days after the adjuvant injection). The degree of ankle-joint swelling was measured with a digital caliper (Mitutoyo, Nakatsugawa, Japan) at 21 days after the adjuvant injection. The rats were killed on day 21 after the first injection of adjuvant. Hind paws of rats were collected and the level of bone destruction was imaged by using a soft X-ray analysis system (SOFTEX: SRO-M 50; SOFTEX, Tokyo, Japan) and the ultra-speed radiographic film (Kodak, Rochester, NY, USA). Tissues were then processed for immunohistochemical analysis.
Immunohistochemistry and Histological Analysis
After fixation by perfusion with 4% (w/v) paraformaldehyde/ PBS, tissue blocks were taken from the hind paws (tarsal bones and tibia) of Lewis rats and immersed in the same fixative for 6 h at 4 1C, followed by washing in PBS overnight at 4 1C. After decalcification in 10% (w/v) ethylene diamine tetraacetate for 3 weeks at 4 1C and dehydration in ethanol series, the tissue blocks were embedded in paraffin. Sections (6 mm) of ankle joints including tibia, talus, and calcaneus were prepared and immunostained. After blocking the nonspecific binding sites with 10% donkey serum and 10% goat serum for 60 min at room temperature, sections were incubated with rabbit polyclonal anti-rat A 2b AR antibody (20 mg/ml; Chemicon, CA, USA). After washing in PBS, sections were incubated with HRP-labeled donkey anti-rabbit IgG (1:200 dilution; Amersham Biosciences, Uppsala, Sweden) for 30 min at room temperature. Color development was performed using a DAB substrate kit (Vector Laboratories, Burlingame, CA, USA).
Statistical Analysis
All data are presented as mean ± s.e.m. Statistical analysis was performed using Student's t-test. Data shown are representative results from three or more independent experiments.
RESULTS

Failure in Suppression of Inflammatory Bone Destruction by Late Stage Administration of MTX in AA Rats
To investigate the therapeutic effects of MTX on osteoclastic bone destruction and hind paw swelling, rats were given injections intraperitoneally with MTX at different timing after adjuvant injection. As shown in Figure 1 , no any clinical symptom was observed in sham-operated rats (Control). Adjuvant injection induced significant inflammation and bone destruction (CFA). MTX suppressed hind paw swelling and bone destruction if administrated 3 days after adjuvant injection (CFA þ MTX 3dB). However, in contrast, MTX did not suppress inflammation as well as bone destruction if it was administrated after the onset of inflammation (10 days after adjuvant injection) (CFA þ MTX 10dB).
Significant Increase in the Level of Plasma Adenosine in AA Rats
Change in the level of adenosine of AA rats was examined by use of HPLC. As shown in Figure 2 , the level of adenosine was significantly increased in response to the progress of arthritis. At first 3 days of adjuvant injection, we could only detect low level of plasma adenosine (0.5-1 mM). However, significant increase in the plasma adenosine was apparent at 10 days. Such high level of plasma adenosine was maintained during the period of severe inflammation and bone destruction.
Adenosine Is Responsive for Abolishment of MTX Action in Osteoclastogenesis
To address the cellular events concerning such MTXinsensitive observed in vivo, we examined the effect of MTX on osteoclastogenesis in vitro by use of whole bone marrow culture system. As shown in Figure 3a (also in Figure 3d ), formation of osteoclast-like MNCs was suppressed by MTX in a dose-dependent manner if the initial culture medium contained no nucleosides and deoxynucleosides. Significant inhibition was apparent at very low concentrations (1 nM) of MTX. As MTX is known to block biosynthesis of nucleosides and deoxynucleosides through inhibiting de novo nucleic acid synthesis, we cultured bone marrow cells in the culture medium containing all nucleosides and deoxynucleosides in order cells could utilize alternative pathway of nucleic acid synthesis, the salvage pathway. Interestingly, osteoclastogenesis was not affected by MTX in the presence of all nucleosides and deoxynucleosides (Figure 3b and d) . These data demonstrated that MTX-mediated inhibition of osteoclastogenesis was completely abolished by the addition of nucleosides and deoxynucleosides in whole bone marrow cultures. We further examined whether MTX-mediated inhibition of osteoclastogenesis occurred through influencing bone marrow stromal cells. As shown in Figure 3c , MTX did not inhibit RANKL-dependent osteoclastogenesis from nonadherent bone marrow cells depleted of stromal cells even in the absence of nucleosides. These data suggest that MTX acts on the bone marrow stromal cells to express inhibitory effects on osteoclastogenesis but it does not directly act on cells in the osteoclast lineage.
As a lack of nucleosides was required for the inhibitory effect of MTX in the bone marrow culture system, we next determined which nucleosides and deoxynucleosides were involved in the abolishment of MTX-induced inhibition of osteoclastogenesis. As shown in Figure 4a , we examined ribonucleosides adenosine, cytidine, guanosine and uridine, and deoxynucleosides deoxyadenosine, deoxycytidine, deoxyguanosine and thymidine. Each nucleoside or deoxynucleoside was added individually to bone marrow cultures of osteoclastogenesis in the presence of MTX at a concentration (100 nM) that completely inhibited osteoclastogenesis, in the absence of nucleosides. The addition of adenosine or deoxyadenosine but not other nucleosides abolished the inhibitory effect of MTX (also in Figure 3d , lower panel). These data strongly suggested that inhibition of osteoclastogenesis by MTX was mediated by blocking adenosine production.
MTX Inhibits RANKL Expression Whereas Adenosine Inhibits OPG Expression
In order to address the mechanism of MTX-induced inhibition of osteoclast formation in bone marrow cultures, we analyzed expression of RANKL using semiquantitative RT-PCR. As shown in Figure 4b , addition of MTX inhibited expression of RANKL mRNA induced by 1a,25(OH) 2 D 3 . On the other hand, expression of OPG mRNA was not affected by the addition of MTX. Addition of adenosine did not influence the level of RANKL mRNA; however, adenosine strongly inhibited the expression of OPG mRNA (Figure 4b ). From these data, it would be possible to consider that MTXinduced suppression of osteoclastogenesis was associated with the suppression of RANKL expression, and that adenosine-mediated recovery of osteoclastogenesis was probably caused by inhibition of OPG expression.
To determine the mechanism by which adenosine inhibits OPG expression, we analyzed expression of the various ARs in rat primary osteoblasts. We analyzed expression of AR mRNA by RT-PCR as shown in Figure 5a . Among the four Adenosine Inhibits MTX Action through A 2b AR To determine which receptor was involved in abolishing MTX-induced suppression of osteoclastogenesis, we assessed the effects of AR antagonists. MTX-induced suppression of osteoclastogenesis was not affected by the addition of caffeine, an antagonist of A 1 AR, A 2a AR, and A 3 AR (Figure 5b) . However, as shown in Figure 5c , abolishment of MTXinduced suppression of osteoclastogenesis was blocked by treatment with MRS1754, a highly selective antagonist for A 2b AR. 22 MRS1754 itself had no significant effect on osteoclastogenesis (Table 1) . These data strongly suggested that the abolishment of MTX-induced suppression in osteoclastogenesis mediated by adenosine was through the low-affinity AR, A 2b AR. To assess an involvement of A 2b AR in inflammatory bone destruction, we examined expression of A 2b AR protein in distal tibia of AA rats with severe bone destruction around the ankle joints by use of immunohistochemistry. As shown in Figure 5d , a significant number of A 2b AR-positive cells were detected at the bonebone marrow interface in the distal tibia of AA rats. No positive cells were observed in the corresponding area of control rats. Normal rabbit IgG (control) showed no staining either in control rats or AA rats. These data show that A 2b AR is significantly expressed in cells located in the bone-bone marrow interface of the distal tibia of AA rats. 
Adenosine Abolishes MTX Influence In Vivo
In the current paper, MTX-induced suppression of osteoclastogenesis in vitro was abolished by the addition of adenosine to the culture medium. We further examined the possibility that adenosine could abolish MTX-induced suppression of osteoclastogenesis in vivo using AA rats. In MTX-treated rats, the swelling of the ankle joints induced by adjuvant injection was dramatically decreased (Figure 6a , CFA þ MTX, and Figure 6b ). When adenosine was injected into the left ankle joints of MTX-treated AA rats, significant hind paw swelling and bone destruction were observed (Figure 6a , CFA þ MTX þ Ad, and Figure 6b ), while MTXinduced suppression of bone destruction was apparent in the right ankle joints only with vehicle injection. These data suggest that high local adenosine concentration at the injection site has abolished the suppressive effect of MTX on inflammation and bone destruction in AA rats. As shown in the X-ray image and histological data, suppression of bone destruction in AA rats induced by the treatment with MTX was abolished by the adenosine treatment. These data suggest an involvement of adenosine in the abolishment of MTXinduced suppression of bone destruction.
DISCUSSION
In the present study, MTX-induced suppression of bone destruction in vivo was diminished by the addition of adenosine. Our current data suggest that adenosine has a key role in MTX insensitivity. We also discovered that adenosine inhibits OPG mRNA expression and affects osteoclastogenesis through A 2b AR. Adenosine is either released from cells or is formed extracellularly by dephosphorylation of extracellular adenosine triphosphate (ATP), followed by diffusion to cell surface ARs expressed on the surface of adjacent cells. 16 The level of extracellular adenosine increases at sites of metabolic stress, inflammation, and infection. For example, a recent study has documented that plasma adenosine levels reach 4-10 mM in patients with sepsis, a condition associated with both ischemia and inflammation, whereas adenosine concentrations in healthy individuals are o1 mM. 16, 23 In the synovial fluid of patients with RA, adenosine concentration may reach the 10-100 mM range. 24, 25 These higher levels of adenosine in inflammation are able to activate the low-affinity receptor, A 2b AR. In AA rats with severe bone destruction, the adenosine level is presumed to be increased as a result of the inflammatory process. In the current study, a marked induction of A 2b AR protein was detected in the area of severe bone destruction in AA rats, suggesting that these areas with severe bone destruction could be regulated by adenosine. Furthermore, caffeine did not abolish suppression of osteoclastogenesis by MTX, suggesting non-involvement of A 1 , A 2a , and A 3 AR in this process. In contrast, A 2b AR appears to be involved in the regulation of inflammation and osteoclastogenesis in RA. A highly selective A 2b AR inhibitor, MRS1754, could be a potential seed of medicine for the treatment of inflammation and bone destruction in RA. In our current study, MTX treatment from 3 days after adjuvant injection markedly suppressed bone destruction as well as osteoclast recruitment, presumably because joint tissues express only low levels of adenosine prior to the initiation of inflammation. In other words, MTX could not suppress osteoclastogenesis if synovial tissue contains high levels of adenosine. In concordance with this hypothesis, injection of MTX at the late stage of AA did not suppress inflammatory bone destruction. In our experiments of adenosine measurement in the plasma of AA rats, adenosine concentration in plasma was markedly elevated during day 3 to day 10 after adjuvant injection. Although we could not measure the level of adenosine in the synovial fluid because of the technical reasons, the adenosine level is supposed to be very high in the synovial fluid as the plasma level of adenosine increased approximately five-folds from day 3 to day 10 after adjuvant injection. Kara et al 26, 27 reported that A 1 AR has a critical role in osteoclast formation and function. In their study, A 1 AR knockout mice showed a reduction in osteoclastogenesis as well as suppressing osteoclast function using in vitro bone marrow culture system. Their findings showed a possible involvement of A 1 AR in normal osteoclastogenesis. Montesinos et al 28, 29 has reported that adenosine acts as the suppressive factor in inflammation. In their model, MTX administration induced a significant level of adenosine; however, its level is o170 nM, which concentration are able to activate only the high-affinity receptors. Several lines of evidence have been reported that A 3 receptor have anti-inflammatory and anti-resorptive effects. 30 In our current study, we have focused on the adenosine-mediated recovery of osteoclastogenesis under the specified condition in which osteoclastogenesis and inflammation are suppressed by MTX. Although more precise quantitative data using micro-CT are required, we could demonstrate that adenosine successfully abolish MTX-induced suppression of bone destruction when it was injected to the joint cavity of AA rats. It would require the high local level of adenosine (of 440 mM) to express such MTX resistance. We have demonstrated a possible involvement of A 2b AR, a low-affinity AR, in this process. Adenosine acts osteoblastic stromal cells mainly through A 2b AR to inhibit OPG production, which allows abundant osteoclastogenesis owing to an increase in the ratio of RANKL/OPG. This mechanism could partly explain the incidence of MTX resistance in some patients with RA. Therefore, simultaneous administration of A 2b AR antagonist and MTX may improve MTX-based therapy for RA patients. Estimation of adenosine in MTX-resistant patients could open a new diagnostic approach to monitor the progress of RA. Further clinical studies are required to establish a correlation of MTX resistance and the level of adenosine in patience with RA.
Genetic studies of tumors have demonstrated amplification of the dihydrofolate reductase (DHFR) gene in MTXresistant patients. Recently, profound progress at the molecular level has been made in research on MTX-resistant tumors. Mechanisms for explaining resistance to MTX treatment include an increase in dihydrofolate reductase (DHFR) enzyme levels, resulting from DHFR gene overexpression, coupled with impaired intracellular transport of MTX as a consequence of decreased levels of reduced folate carrier (RFC) at the cell membrane. 31 Serra et al 32 demonstrated amplification of the DHFR gene in MTX-resistant osteosarcoma patients. MTX uptake is dependent on RFC. Defective drug uptake in association with decreased RFC is a common mechanism of MTX resistance in many tumor types. Yang et al 33 demonstrated that partial promoter methylation and RFC mRNA downregulation were observed in a cell line established from a patient with malignant fibrohistiocytoma. Even if MTX is taken up by target cells, MTX can be polyglutamylated by folylpolyglutamate synthetase (FPGS); polyglutamylated MTX is subjected to extensive cellular retention, which results in maximal cytotoxic activity. Recently, Stark et al 34 reported aberrant splicing of FPGS in anti-folate resistance in leukemia. Such genetic mutations observed in tumor cells are usually irreversible. In contrast, in our current experiments, adenosine treatment completely abolished MTX-induced suppression of bone destruction in AA rats. This may suggest that MTX resistance in RA is reversible. As RA is an autoimmune disease, it is unlikely that MTX resistance occurs by mutation as observed in MTX-resistant tumors. However, as rheumatoid pannus is considered as a pseudo-tumor, similar molecular mechanisms as tumors may exist in MTX observed in RA. Further studies should be addressed to evaluate a possible involvement of molecular mechanism of MTX resistance similar to tumors.
Several reports have addressed the suppressive effect of MTX on osteoclastogenesis. 35, 36 We also showed, in the current study, that MTX dramatically suppressed RANKL mRNA levels, which is in accord with data of other groups. Adenosine did not affect MTX-induced suppression of RANKL; however, adenosine markedly suppressed expression of OPG mRNA. The decrease in the level of OPG results in an increase in the ratio of RANKL/OPG, causing a recovery of Figure 6 Adenosine treatment abrogated MTX-induced suppression of bone destruction in AA rats. MTX injections (1 mg/kg/week) were given intraperitoneally beginning on day 3 after the adjuvant injection. Adenosine was injected into the cavity of the left ankle joints as described in Materials and methods. The injections were performed every 3 days beginning on day 3 after the adjuvant injection. PBS was injected into the right ankle joint as an internal vehicle control. (a) Representative photographs (left panels), X-ray images (middle panels), and histologic staining (right panels) of the hind paws. Adjuvant injection induced inflammation and bone destruction. In MTX-treated rats (from day 3 after adjuvant injection), the swelling of ankle joint and bone destruction was dramatically decreased. In contrast, when adenosine was injected into the left ankle joints of AA rats treated with MTX, hind paw swelling and bone destruction at the injected sides was increased (CFA þ MTX þ Ad) to the level seen in adjuvant-treated AA rats (CFA). Ti, tibia; Ta, tarsus; SM, synovial membrane. Bars ¼ 200 mm. (b) Quantitative demonstration of ankle-joint swelling in AA rats. In AA rats with MTX treatment from day 3 after adjuvant injection, the volume was reduced to the level of controls. In contrast, MTX-induced suppression of joint swelling was canceled by injection of adenosine. Each column and bar represents the mean±s.e.m. of four rats. Data were analyzed by Student's t-test. **Po0.01 and ***Po0.001 when compared with control rats. # Po0.05 when compared each pair.
Adenosine receptor in adjuvant-induced arthritis J Teramachi et al osteoclastogenesis. Evans et al 37 reported that human osteoblasts produce adenosine and that adenosine has an autocrine or paracrine role in the inhibition of production of OPG protein. We demonstrated that adenosine inhibits gene expression of OPG, possibly through A 2b AR. Evans et al (2006) demonstrated that endogenous adenosine acts on osteoblastic cells to increase IL6 release. It is also possible to consider that adenosine acts through upregulation of IL6 in our experimental systems to augment osteoclastogenesis. MRS1754, a highly selective antagonist for A 2b AR, might be useful in overcoming MTX resistance in RA patients. Extracellular ATP is known to support osteoclast function through formation of the sealing zone and the secretion of lytic granules required for osteoclast function via P2X7 nucleotide receptors. 38, 39 Extracellular ATP is promptly converted into AMP and adenosine by the sequential action of CD39 (NTPDase) and CD73 (Ecto5 0 NTase), which results in an increase in the local level of adenosine to the 10-100 mM level. In the MTX-resistant conditions in inflammatory bone destruction, a high level of extracellular adenosine produced in the inflammatory sites could inhibit production of OPG, and allows formation of abundant osteoclasts and consequent severe bone destruction.
Recently, anti-TNFa therapy has been shown to be successful in MTX-resistant RA patients; however, severe side effects of this treatment were also reported. 10 Blockage of adenosine-A 2b AR could provide a milder, but effective, therapy with minimal side effects in comparison to an intensive therapy such as anti-TNFa.
We found that MTX-induced suppression of bone destruction was abolished by extracellular adenosine through suppression of OPG expression. The uptake of extracellular adenosine via adenosine-A 2b AR receptor system appears to explain MTX resistance in RA. Careful utilization of MTX considering the dose is quite important 40 and parallel utility with other safer medicine is considered to be more effective. Our study provides basic information concerning the development of a novel therapy to overcome MTX resistance in inflammatory bone destruction by use of specific antagonists for ARs.
